Status
Conditions
Treatments
About
The study will assess whether changes in kinetic parameters of tumor and peritumoral vasculature using ultrafast dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with breast cancer appropriate for NAC. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Female;
Age 18 years or older;
Diagnosis of invasive breast cancer by ultrasound guided biopsy;
Planed for receiving neoadjuvant chemotherapy (NAC) 4. Planned definitive breast surgery following completion of NAC.
Exclusion criteria
Loading...
Central trial contact
Yajia Gu, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal